AbbVie Inc (ABBV)vsCharming Medical Limited Class A Ordinary Shares (MCTA)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
MCTA
Charming Medical Limited Class A Ordinary Shares
$29.36
0.00%
HEALTHCARE · Cap: $504.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1127647% more annual revenue ($61.16B vs $5.42M). MCTA leads profitability with a 12.1% profit margin vs 6.9%. ABBV trades at a lower P/E of 100.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MCTA
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for MCTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 81.0% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 1467.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MCTA
The strongest argument for MCTA centers on EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MCTA
The primary concerns for MCTA are Market Cap, Return on Equity, P/E Ratio. A P/E of 419.4x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while MCTA is a declining play — different risk/reward profiles.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 27/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Charming Medical Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?